Loading
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Latest quote
$3.61
−$0.09 · -2.43%
After-hours
$3.56
−$0.05 · -1.39%
Sep 9, 7:59 PM ET
Regular session · ET · Market data may be delayed.
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Day range
Current $3.61
52-week range
Current $3.61
Regular session · ET · Market data may be delayed.
GoAI Score
Strong sell
Valuation
2
Overpriced
Sentiment
45
Mixed
Risk
82
Extreme Risk
Momentum
31
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Day range
Current $3.61
52-week range
Current $3.61
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CHF) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 29.97K CHF | 404.1K CHF | 1.61M CHF | 1.42M CHF | 2.92M CHF |
| Gross profit | 29.97K CHF | 404.1K CHF | 1.61M CHF | 1.42M CHF | 2.92M CHF |
| Research and development | 190.19K CHF | 435.19K CHF | 942.71K CHF | 7.88M CHF | 9.01M CHF |
| Selling, general, and administrative | 1.89M CHF | 1.68M CHF | 2.03M CHF | 3.26M CHF | 7.75M CHF |
| Operating expenses | 2.84M CHF | 3.16M CHF | 3.86M CHF | 11.96M CHF | 18.42M CHF |
| Interest income | — | 9.17K CHF | 63.96K CHF | 29.25K CHF | 5.32K CHF |
| Interest expense | 2.42K CHF | 3.55K CHF | 21.61K CHF | 48.9K CHF | 63.01K CHF |
| Depreciation and amortization | 8.47K CHF | 260.12K CHF | 305.95K CHF | 323.14K CHF | 347.61K CHF |
| Operating income | −2.81M CHF | −2.76M CHF | −2.24M CHF | −10.54M CHF | −15.51M CHF |
| Net income | −6.73M CHF | 7.06M CHF | −10.56M CHF | −20.8M CHF | −15.35M CHF |
Company facts updated Sep 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$30.00
731.02% upsideAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
